Not much movement in ONXX today. I assume this is because Regorfenib approval was expected, and the boost to ONXX bottom-line isn't going to be great considering the market size and the 20% share ONXX gets. Perhaps adding approval for GIST will provide a bit more of a jump. However, the big news people are likely waiting for is how sales of Carfilzomib start out.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.